| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Divisions of Hematologic Malignancies [I. C. A., M. A. S.] and Pharmacology [B. A. T.], Department of Medicine, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, and Celltech Therapeutics Ltd., Slough, Berkshire, United Kingdom [A. J. P. D.]
The efficacy of combination therapy including an oral gelatinase inhibitor (CT1746) and cytotoxic agent was analyzed using the murine Lewis lung carcinoma model. Primary tumors, pulmonary metastases, and sera from tumor-bearing animals had increased gelatinase B activity that was inhibited by CT1746 levels achievable in vivo. The combination of CT1746 and cyclophosphamide (CTX) was significantly more effective than either single agent in delaying local tumor growth (CT1746/CTX, 30.9 ± 1.7 days; CT1746, 2.6 ± 0.3 days; CTX, 19.5 ± 1.1 days; P < .001) and reducing the number and size of pulmonary metastases [CT1746/CTX, 5 ± 2 (15% metastases > 3 mm); CT1746, 15 ± 4 (55% > 3 mm); CTX, 11 ± 3 (63% > 3 mm); no treatment, 24 ± 5 (62% > 3 mm); P < .001]. These data support the notion of combining matrix metalloproteinase inhibitors and cytotoxic agents to treat certain epithelial malignancies.
1 To whom requests for reprints should be addressed, at Division of Hematologic Malignancies, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115.
Received 12/12/95. Accepted 1/ 2/96.
This article has been cited by other articles:
|
|
 |
|
  J. S. Rao, C. Gondi, C. Chetty, S. Chittivelu, P. A. Joseph, and S. S. Lakka Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells Mol. Cancer Ther., September 1, 2005; 4(9): 1399 - 1408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Trexler, K. Briknarova, M. Gehrmann, M. Llinas, and L. Patthy Peptide Ligands for the Fibronectin Type II Modules of Matrix Metalloproteinase 2 (MMP-2) J. Biol. Chem., March 28, 2003; 278(14): 12241 - 12246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Su, Y.-Q. Wei, L. Tian, X. Zhao, L. Yang, Q.-M. He, Y. Wang, Y. Lu, Y. Wu, F. Liu, et al. Active Immunogene Therapy of Cancer with Vaccine On the Basis of Chicken Homologous Matrix Metalloproteinase-2 Cancer Res., February 1, 2003; 63(3): 600 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Yan, H. Wang, Y. Toh, and D. D. Boyd Repression of 92-kDa Type IV Collagenase Expression by MTA1 Is Mediated through Direct Interactions with the Promoter via a Mechanism, Which Is Both Dependent on and Independent of Histone Deacetylation J. Biol. Chem., January 17, 2003; 278(4): 2309 - 2316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Groves, V. K. Puduvalli, K. R. Hess, K. A. Jaeckle, P. Peterson, W.K. Alfred Yung, and V. A. Levin Phase II Trial of Temozolomide Plus the Matrix Metalloproteinase Inhibitor, Marimastat, in Recurrent and Progressive Glioblastoma Multiforme J. Clin. Oncol., March 1, 2002; 20(5): 1383 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hoekstra, F.A.L.M. Eskens, and J. Verweij Matrix Metalloproteinase Inhibitors: Current Developments and Future Perspectives Oncologist, October 1, 2001; 6(5): 415 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Nelson, B. Fingleton, M. L. Rothenberg, and L. M. Matrisian Matrix Metalloproteinases: Biologic Activity and Clinical Implications J. Clin. Oncol., March 1, 2000; 18(5): 1135 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Aparicio, S. Kermorgant, V. Dessirier, M. J.M. Lewin, and T. Lehy Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats Carcinogenesis, August 1, 1999; 20(8): 1445 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Shalinsky, J. Brekken, H. Zou, L. A. Bloom, C. D. McDermott, S. Zook, N. M. Varki, and K. Appelt Marked Antiangiogenic and Antitumor Efficacy of AG3340 in Chemoresistant Human Non-Small Cell Lung Cancer Tumors: Single Agent and Combination Chemotherapy Studies Clin. Cancer Res., July 1, 1999; 5(7): 1905 - 1917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Price, Q. Shi, D. Morris, M. E. Wilcox, P. M. A. Brasher, N. B. Rewcastle, D. Shalinsky, H. Zou, K. Appelt, R. N. Johnston, et al. Marked Inhibition of Tumor Growth in a Malignant Glioma Tumor Model by a Novel Synthetic Matrix MetalloproteinaseInhibitor AG3340 Clin. Cancer Res., April 1, 1999; 5(4): 845 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Wilkinson, J. J. T. Owen, and E. J. Jenkinson Factors Regulating Stem Cell Recruitment to the Fetal Thymus J. Immunol., April 1, 1999; 162(7): 3873 - 3881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Cox, W P Steward, and K J O'Byrne The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer Thorax, February 1, 1999; 54(2): 169 - 179. [Full Text]
|
|
|
|
|
|
S. Zucker, M. Drews, C. Conner, H. D. Foda, Y. A. DeClerck, K. E. Langley, W. F. Bahou, A. J. P. Docherty, and J. Cao Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) Binds to the Catalytic Domain of the Cell Surface Receptor, Membrane Type 1-Matrix Metalloproteinase 1 (MT1-MMP) J. Biol. Chem., January 9, 1998; 273(2): 1216 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Bugge, K. W. Kombrinck, Q. Xiao, K. Holmback, C. C. Daugherty, D. P. Witte, and J. L. Degen Growth and Dissemination of Lewis Lung Carcinoma in Plasminogen-Deficient Mice Blood, December 1, 1997; 90(11): 4522 - 4531. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
